Ionis Pharmaceuticals (IONS) Price & Analysis

Compare

1,472 Followers

IONS Stock Chart & Stats

$86.50

-$0.75(-2.14%)

At close: Jan 08 4:00 PM EST

$86.50

-$0.75(-2.14%)

Day’s Range― - ―

52-Week Range$23.95 - $86.74

Previous CloseN/A

Volume126.35K

Average Volume (3M)2.08M

Market Cap

$14.01B

Enterprise Value$14.91B

Total Cash (Recent Filing)$2.24B

Total Debt (Recent Filing)$1.49B

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Feb 25, 2026

EPS Estimate

-1.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding161,974,400

10 Day Avg. Volume2,086,634

30 Day Avg. Volume2,076,754

Financial Highlights & Ratios

PEG Ratio-0.61

Price to Book (P/B)8.88

Price to Sales (P/S)7.41

P/FCF Ratio-9.57

Enterprise Value/Market Cap1.06

Enterprise Value/Revenue15.42

Enterprise Value/Gross Profit15.61

Enterprise Value/Ebitda-97.04

Forecast

1Y Price Target

$97.22

Price Target Upside12.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyAnalysts note that robust trial results showing rapid and durable triglyceride reductions and clear reductions in acute pancreatitis strengthen the drug's clinical value and support strong prescriber demand.

Commercial PotentialManagement-reported early sales outperformance combined with a competitive pricing strategy could encourage broad payer coverage and support substantial long-term revenue upside.

Regulatory ProgressAnalyst commentary highlights Breakthrough Therapy Designations and enhanced agency engagement that could accelerate regulatory review and create earlier commercialization opportunities.

Bears Say

Forecast AssumptionsAnalysts flag uncertainty whether raised sales outlooks reflect true patient uptake or optimistic pricing assumptions, creating downside risk if assumptions are not realized.

Pricing PressureHigh proposed pricing raises the risk of payer-imposed restrictions, and entry of a significantly discounted competitor could meaningfully erode market share and uptake.

Safety UncertaintyOutstanding questions about increases in liver fat fraction and other safety markers for investigational therapies create adoption risk and could slow prescriber or payer acceptance.

Ionis Pharmaceuticals News

Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $87 from $77 and keeps an...

4d ago

IONS

Ionis Pharmaceuticals assumed with an Overweight at Barclays

Barclays assumed coverage of Ionis Pharmaceuticals (IONS) with an Overweight rating and $95 price target Barclays initiated coverage...

14d ago

IONS

Ionis Pharmaceuticals announces European Commission approval for Dawnzera

Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the European Commission has approved Dawnzera in the European Union...

20d ago

IONS

Cathie Wood Doubles Down on High-Potential Biotech Plays

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Monday, January 12, as revealed in daily fund...

28d ago

TER

TXG

RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks

Cathie Wood made several trades across her ARK ETFs on Tuesday, January 6, 2026, according to daily trade...

1M ago

KDK

Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on IONS stock, giving a Buy rating on...

1M ago

IONS

Ionis Advances Bepirovirsen After Positive Phase 3 Results

The latest update is out from Ionis Pharmaceuticals ( ($IONS) ). On January 7, 2026, Ionis Pharmaceuticals reported...

1M ago

IONS

Ionis partner GSK reports B-Well 1, B-Well 2 studies met primary endpoint

Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced results from two pivotal Phase 3 studies, B-Well 1 and B-Well...

1M ago

GSK

IONS

Ionis Pharmaceuticals price target raised to $100 from $82 at Wells Fargo

Wells Fargo raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $82 and keeps an...

1M ago

IONS

Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold

On the last trading day of 2025, Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech...

1M ago

BEAM

Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and growth stocks on Tuesday, December 30,...

1M ago

BEAM

IONS

IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks

Cathie Wood made a few trades across ARK ETFs on Friday, December 19, 2025, based on the daily trade filings....

2M ago

IBTA

IONS

Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $82...

2M ago

IONS

Arrowhead price target raised to $100 from $70 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $100 from $70 and...

2M ago

ARWR

IONS

IONS FAQ

What was Ionis Pharmaceuticals’s price range in the past 12 months?

Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $86.74 in the past 12 months.

What is Ionis Pharmaceuticals’s market cap?

Ionis Pharmaceuticals’s market cap is $14.01B.

When is Ionis Pharmaceuticals’s upcoming earnings report date?

Ionis Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 15 days.

How were Ionis Pharmaceuticals’s earnings last quarter?

Ionis Pharmaceuticals released its earnings results on Oct 29, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.418.

Is Ionis Pharmaceuticals overvalued?

According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals pay dividends?

Ionis Pharmaceuticals does not currently pay dividends.

What is Ionis Pharmaceuticals’s EPS estimate?

Ionis Pharmaceuticals’s EPS estimate is -1.32.

How many shares outstanding does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals has 161,974,400 shares outstanding.

What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?

Ionis Pharmaceuticals reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -2.297%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals?

Currently, no hedge funds are holding shares in IONS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ionis Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-39.99%

Trailing 12-Months

Asset Growth

-1.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals (IONS) Earnings & Revenues

Historic Earnings Reports

IONS Company Deck

IONS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ionis Pharmaceuticals demonstrated strong revenue growth and successful product launches, with significant advancements in their clinical pipeline. Despite these achievements, the company faces challenges with operating losses and patient identification for Tringolza. Overall, the positive developments outweigh the challenges.View all IONS earnings summaries

IONS Revenue Breakdown

60.82% R&D

39.18% Commercial

IONS Stock 12 Month Forecast

Average Price Target

$97.22

▲(12.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","111":"$111","47.25":"$47.3","68.5":"$68.5","89.75":"$89.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$87.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,47.25,68.5,89.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.07,85.14153846153846,87.21307692307691,89.28461538461538,91.35615384615384,93.4276923076923,95.49923076923076,97.57076923076923,99.6423076923077,101.71384615384615,103.78538461538461,105.85692307692307,107.92846153846153,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.07,84.15846153846154,85.24692307692307,86.33538461538461,87.42384615384614,88.51230769230769,89.60076923076923,90.68923076923076,91.7776923076923,92.86615384615385,93.95461538461538,95.04307692307692,96.13153846153845,{"y":97.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.07,83.37230769230769,83.67461538461538,83.97692307692307,84.27923076923076,84.58153846153846,84.88384615384615,85.18615384615384,85.48846153846154,85.79076923076923,86.09307692307692,86.39538461538461,86.69769230769231,{"y":87,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >